Compare CSPI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | BNR |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.6M | 76.5M |
| IPO Year | 1994 | 2019 |
| Metric | CSPI | BNR |
|---|---|---|
| Price | $9.15 | $8.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.9K | 22.5K |
| Earning Date | 05-08-2026 | 06-05-2026 |
| Dividend Yield | ★ 1.15% | N/A |
| EPS Growth | ★ 75.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $217.75 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.55 | $3.06 |
| 52 Week High | $15.00 | $41.72 |
| Indicator | CSPI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 50.89 | 37.48 |
| Support Level | $9.02 | $8.04 |
| Resistance Level | $10.15 | $9.90 |
| Average True Range (ATR) | 0.66 | 0.77 |
| MACD | -0.02 | 0.23 |
| Stochastic Oscillator | 64.76 | 51.87 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.